Induced endothelial cells from peripheral arterial disease patients and neonatal fibroblasts have comparable angiogenic properties

Jack D. Hywood1,2‡*, Sara Sadeghipour1‡, Zoe E. Clayton1,2, Jun Yuan1, Colleen Stubbs3, Jack W. T. Wong4, John P. Cooke5, Sanjay Patel1,2,6

1 Heart Research Institute, Newtown, NSW, Australia, 2 Sydney Medical School, University of Sydney, Camperdown, NSW, Australia, 3 RNACore, Houston Methodist Research Institute, Houston, Texas, United States of America, 4 School of Life Sciences, Chinese University of Hong Kong, Hong Kong, China, 5 Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, Texas, United States of America, 6 Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia

* These authors contributed equally to this work.
‡ These authors are joint first authors on this work.

Abstract

Induced endothelial cells (iECs) generated from neonatal fibroblasts via transdifferentiation have been shown to have pro-angiogenic properties and are a potential therapy for peripheral arterial disease (PAD). It is unknown if iECs can be generated from fibroblasts collected from PAD patients and whether these cells are pro-angiogenic. In this study fibroblasts were collected from four PAD patients undergoing carotid endarterectomies. These cells, and neonatal fibroblasts, were transdifferentiated into iECs using modified mRNA. Endothelial phenotype and pro-angiogenic cytokine secretion were investigated. NOD-SCID mice underwent surgery to induce hindlimb ischaemia in a murine model of PAD. Mice received intramuscular injections with either control vehicle, or 1 × 10^6 neonatal-derived or 1 × 10^6 patient-derived iECs. Recovery in perfusion to the affected limb was measured using laser Doppler scanning. Perfusion recovery was enhanced in mice treated with neonatal-derived iECs and in two of the three patient-derived iEC lines investigated in vivo. Patient-derived iECs can be successfully generated from PAD patients and for specific patients display comparable pro-angiogenic properties to neonatal-derived iECs.

1. Background

Peripheral arterial disease (PAD) is a significant contributor to global mortality and morbidity [1–4]. Revascularisation procedures are the gold standard therapy for severe disease [2, 5]. However, substantial subsets of patients are unsuitable for surgical or endovascular interventions due to pre-existing morbidity or an extremely calcified vasculature [6], and restenosis and/or thrombosis of vessels or bypass conduits is common after an intervention [7–10]. Therapeutic angiogenesis via cellular therapy, the stimulation and augmentation of vessel
formation via the administration of exogenous cells [11], is a promising strategy for treating such patients [12].

Endothelial-like cells produced from induced pluripotent stem cells (iPSCs) have been demonstrated to be pro-angiogenic in pre-clinical models [13–18]. Recently, dermal fibroblasts have been transdifferentiated to endothelial-like cells, referred to as induced endothelial cells (iECs) [16, 19–22]. The potential benefits of direct transdifferentiation of somatic cells to iECs over reprogramming to full pluripotency to produce endothelial-like cells include potentially reducing production times and increased efficiency [16, 23–25]. Multiple studies have found that iECs possess pro-angiogenic properties, augmenting the restoration of blood flow in pre-clinical murine models of PAD [16, 19–21], with iECs shown to be equivalent to endothelial-like cells derived from iPSCs [16].

Recent results obtained for human iECs produced using lentiviral vector induced over-expression of transcription factors ETV2, FLI1, GATA2 and KLF4 used neonatal fibroblasts as the somatic cell type undergoing transdifferentiation [16]. However, the therapeutic promise of reprogrammed cells such as iECs lies in the capacity for autologous iECs to be produced directly from a patient’s somatic cells. Such patient-derived cells would theoretically have reduced immunogenicity upon transplantation back into the patient [24–26]. In addition, the use of lentiviral vectors in reprogramming, in particular producing iPSCs, has been demonstrated the cause genetic, epigenetic, and transcriptional abnormalities [27–30]. A non-integrating transdifferentiation strategy may be safer and have a simpler regulatory roadmap [16, 22]. Non-integrating factors, such as mmRNA, have been used successfully in reprogramming to pluripotency and transdifferentiation and offer a means of producing clinical grade cells [31–36]. In contrast, alternative techniques such as the use of small molecules alone in reprogramming is relatively inefficient [37, 38].

Given the above, it is yet been determined whether the pro-angiogenic effects previously shown in iECs can be replicated in iECs generated from patients with advanced atherosclerotic disease. Such patients are typically of advanced age and have an array of risk factors including smoking, diabetes, hypertension, hyperlipidaemia, among others. Determining whether patient-derived iECs are pro-angiogenic is an important step to determining whether these cells may be therapeutic in patients with cardiovascular disease. In addition, we wished to assess the feasibility of using modified messenger mRNA (mmRNA) encoding the transdifferentiation factors, rather than viral vectors.

Our objective was to perform a proof of concept study to determine whether dermal fibroblasts obtained from PAD patients could be transdifferentiated into iECs using mmRNA, and to establish whether they had comparable properties found in neonatal-derived iECs. We carried out assays to directly compare the in vitro characteristics of neonatal-derived and patient-derived iECs. The recovery of blood flow in a murine hindlimb ischaemia model of PAD was measured using laser Doppler to compare the in vivo pro-angiogenic capacity of the neonatal-derived and patient-derived iECs. Our results indicate that patient derived iECs possessed similar angiogenic properties to neonatal-derived iECs. These findings support the concept that iECs could be produced for therapeutic purposes from PAD and CAD patients.

2. Methods

2.1. Establishing patient derived cell cultures

Human dermal fibroblasts were isolated from 5mm full-thickness skin biopsies obtained from four peripheral arterial disease patients undergoing carotid endarterectomies. Biopsies were collected from the site of incision. This research was approved by the Sydney Local Health District Ethics Review Committee (Protocol No X14-0240), and informed consent was obtained.
and documented from all individuals. Deidentified fibroblast cultures were derived via the
explant method [39], with dermal samples expanded on a gelatine-based 6-well plate and incu-
bated with Hi-glucose DMEM containing 20% foetal bovine serum (FBS) media (with 1% NaPyruvate, penicillin and streptomycin, L-glutamine). When cells were confluent they were
passaged to T75 flasks at 1:2. Reprogramming was initiated on passage 2 or 3.

2.2. Transdifferentiation

Patient derived adult fibroblasts, and human neonatal foreskin BJ fibroblasts (American Type
Culture Collection (ATCC), Manassas, VA 20108), were seeded on 6-well gelatine coated
plates in DMEM containing 10% FBS (with 1% NaPyruvate, penicillin and streptomycin, L-
glutamine) overnight before transfection. Cells were transfected over 14 days, with mmRNA
(RNACore, 6670 Bertner Avenue, Houston, Texas 77030) encoding ETV2, FLI1, GATA2, and
KLF4 each day in the presence of Lipofectamine RNAiMAX (13778–075, L3484, Life Technol-
gies Australia Pty Ltd., Scoresby, VIC 3179). In generating the mmRNA, we replaced uridine
with pseudouridine and replaced cytosine with 5-methylcytosine, so as to reduce innate
immune activation [40]. The cells were incubated in DMEM with 7.5% FBS and 7.5% knock-
out serum replacement with 0.2 μg/ml B18R for the first 3 days, DMEM with 7.5% FBS and
10% knockout serum replacement with 0.2 μg/ml B18R, 50 ng/mL vascular endothelial growth
factor, 20 ng/mL basic fibroblast growth factor, and 20 ng/mL BMP4 for days 4–7, and DMEM
with 7.5% FBS and 10% knockout serum replacement with 0.2 μg/ml B18R, 50 ng/mL vascular
endothelial growth factor, 20 ng/mL basic fibroblast growth factor, and 0.1mM 8-Bromo
cAMP for days 8–14. After 14 days, cells were sorted for CD31+ using a CD31 Microbead kit
and an OctoMACS Separator (130-091-935, Miltenyi Biotec Australia Pty. Ltd., Unit 16 A, 2
Eden Park Drive, Macquarie Park, NSW 2113, Australia). Sorted cells were cultured using EC
growth medium EGM-2MV (CC3202, Lonza Group Ltd.) and a TFG-β inhibitor, SB341542
(10 μmol/L).

2.3. In vitro experiments

In vitro experiments were conducted comparing neonatal-derived iECs and patient-derived
iECs. To examine for endothelial cell marker expression cells were fixed with PBS + 4% para-
formaldehyde and stained with DAPI and anti-CD31 (560983, BD Biosciences, Becton, Dick-
inson and Company, 1 Becton Drive, Franklin Lakes, NJ 07417–1880, USA), with images
obtained at 10X magnification. For the Matrigel tubulogenesis assay 1 × 10⁴ cells/well were
seeded on 6 wells of a 96-well plate coated with 35 μL of growth factor reduced Matrigel (Fal-
con, FAL356231, In Vitro Technologies, 7–9 Summit Rd., Noble Park North, VIC 3174, Aus-
tralia) and incubated in EBM + 1% FBS for 24 hrs. Images were taken at 5 and 24 hours after
seeding. To measure acetylated LDL uptake 5 × 10⁴ cells/well were seeded on 3 wells of a
24-well plate in EGM2-MV. After 24 hours the cells were incubated with Dil-labeled acety-
lated-LDL (Low Density Lipoprotein from Human Plasma, Acetylated, Dil complex, L3484,
Life Technologies Australia Pty Ltd., Scoresby, VIC 3179) for 4 hours and with UEA lectin
(Lectin from Ulex europaeus, FITC conjugate, L9006, Sigma-Aldrich, 3050 Spruce St.,
St. Louis, MO 63103, USA) for 30 minutes prior to imaging. Migration towards VEGF was
measured using a Boyden chamber assay; 1.1 × 10⁴ cells/well were seeded in transwells (8 μm
pore size, Corning Transwell, CLS 3421–22, Sigma-Aldrich, 3050 Spruce St., St. Louis, MO
63103, USA) in 600 μL EBM2 + 2% FBS media and these were inserted into 24 well plates.
Experimental wells (3 wells) contained 600 μL EBM + 2% FBS and 10 ng/mL VEGF, while con-
trol wells (3 wells) contained EBM + 2% FBS alone, without VEGF. The cells were incubated
for 24 hours. Transwell membranes were then washed, fixed with 70% ethanol, and stained.
with UEA lectin and DAPI. The total number of cells that had moved to the opposite side of the membranes were counted to assess migration. Cytokine secretion was measured in conditioned media for each cell line. Neonatal-derived iECs, patient-derived iECs, and human coronary artery endothelial cells (HCAECs) were seeded on 6 well culture plates (1 × 10^5 cells/well). After 24 hours, the media was changed to EBM2 + 2% FBS and the cells were incubated for 24 hours, under either hypoxic (1.2% O2) or normoxic (21% O2) conditions. The conditioned media was centrifuged at 2000 rpm for 10 min, before being stored at -80˚C. The concentrations of a selection of angiogenic cytokines, VEGF, HGF, PI GF, SDF-1, FGF-1, FGF-2, and Leptin were measured using the Luminex polystyrene bead-based multiplex assay (Luminex High Performance Human Screening Assay, LXSAH-07, R&D Systems, Inc. Minneapolis, MN 55413, USA) as per manufacturer’s instructions. All samples were run in duplicate with three biological replicates for each cell line.

### 2.4. Hindlimb ischaemia model

In a murine model of PAD adapted from that developed by Niiyama et al. [41], Male NOD/SCID mice, aged 8 weeks, underwent unilateral femoral artery and vein ligation and removal to induce hindlimb ischaemia. Mice were randomly allocated to either the control group or one of the cell treatment groups, which included one neonatal-derived iEC treatment group, and three separate patient-derived iEC treatment groups. Immediately after surgical ligation and excision of the femoral vessels the mice received intramuscular injections of either 1 × 10^6 neonatal-derived iECs in EBM media, 1 × 10^6 patient-derived iECs in EBM media, or EBM media (n = 26 controls, 9 per treatment group). Cells were administered as two 25 μL injections into the adductor muscle adjacent to the site of the femoral vessels prior to removal. Perfusion in both hindlimbs for each mouse was measured using laser Doppler on days 0, 1, 2, 4, 6, 8, 10 and 14 post-surgery. During the surgical procedure and laser Doppler measurements the mice were anaesthetised via 1% isoflurane inhalation and positioned on a heat mat. Five repeat measurements were taken 5 minutes after anaesthetic induction, with the maximal perfusion measurement used in analysis.

At completion of the study gastrocnemius muscles were removed and snap frozen in OCT, with 5 μm sections of these samples stained with anti-CD31, anti-laminin (ab25644 and ab11576 respectively, Abcam plc. 330 Science Park, Cambridge CB4, UK) and anti-α smooth muscle actin (F3777, Sigma-Aldrich, 3050 Spruce St., St. Louis, MO 63103, USA) antibodies. Capillary density was measured by counting the number of capillaries per myocyte for each section.

Animal studies were approved by the Sydney Local Health District Animal Welfare Committee (Protocol Number 2015/020) and conducted in accordance with the National Health and Medical Research Centre (NHMRC) Guidelines for the care and use of animals for scientific purposes.

### 2.5. Statistical analysis

Data is presented here as mean ± SEM. Statistical analyses were performed using GraphPad Prism version 7.0b for Mac OS X, (GraphPad Software, La Jolla, California, USA). The Student’s t-test was employed for comparisons between 2 groups and ANOVA with Bonferroni post hoc testing for comparisons of multiple groups. Statistical significance is indicated at p < 0.05.

### 3. Results

#### 3.1. Establishing patient-derived fibroblast cell lines

Dermal fibroblast cell lines established for four PAD patients were used for transdifferentiation and analysed in the in vitro studies. Throughout the remainder of this paper they are referred
to as patients 1, 2, 3, and 4. Of these, patients 1, 2, and 3 were used for the \textit{in vivo} hindlimb ischaemia study. The logistical constraint of slow cell growth precluded us from using the patient 4 cell line in the \textit{in vivo} study. Patients had an array of cardiovascular risk factors including smoking, type 2 diabetes mellitus, hyperlipidaemia, and hypertension. Details associated with each patient are presented in Table 1. Values listed were obtained prior to surgery.

### 3.2. Transdifferentiation of neonatal and patient derived fibroblasts to iECs

Upon completion of the transdifferentiation protocol CD31+ cells were successfully sorted from remaining cells. Neonatal and patient-derived iECs demonstrated CD31 expression via immunofluorescence (Fig 1).

| Patient | Age | Gender | Hyperlipidaemia | DM (HbA1c) | Smoking (Pack years) | HTN | BMI |
|---------|-----|--------|-----------------|-------------|----------------------|-----|-----|
| 1       | 64  | Female | Yes             | Yes (7.2%)  | Yes (56)             | Yes | 27  |
| 2       | 64  | Male   | Yes             | Yes (7.4%)  | Yes (40)             | Yes | -   |
| 3       | 70  | Male   | Yes             | Yes (8.4%)  | Yes (40)             | Yes | 18.9|
| 4       | 88  | Male   | Yes             | Yes (7.9%)  | No                   | Yes | 30.1|

DM: diabetes mellitus type 2. HTN: hypertension.

https://doi.org/10.1371/journal.pone.0255075.t001

**Table 1. Basic information regarding specific cardiovascular risk factors associated with patients who donated skin samples.**

![Representative immunofluorescence images of neonatal and patient-derived iECs. CD31 (red) immunofluorescence for (a) HCAECs, (b) neonatal-derived iECs; (c) Patient 1; (d) Patient 2; (e) Patient 3; (f) Patient 4, with cell nuclei stained purple using DAPI. Scale bars are 500 μm.](https://doi.org/10.1371/journal.pone.0255075.g001)
3.3. Neonatal-derived and patient-derived iECs behaviour in vitro

Patient-derived iECs were compared against neonatal-derived iECs and HCAECs *in vitro*. In comparison to neonatal-derived iECs the capacity for branching was heterogeneous between patient-derived iEC lines (Fig 2); qualitatively similar tubulogenesis was displayed by patients 2 and 4, while patients 1 and 3 displayed limited tubule formation. Both neonatal and patient-derived iECs bound UEA lectin 1, but had limited uptake of acetylated-LDL (Fig 3). Non-significant positive trends in migration across Transwells in response to VEGF were found for each cell line (S1 Fig).

Using a multiplex assay, we tested conditioned media from HCAECs, neonatal-derived iECs, and each patient-derived iEC line for the secretion of angiogenic cytokines under normoxic and hypoxic conditions (Fig 4). HCAECs secreted detectable levels of VEGF, HGF, FGF-2, and PlGF. Neonatal-derived iECs demonstrated detectable secretion of VEGF and FGF-2. Patient-derived iECs demonstrated detectable secretion of VEGF, HGF, and FGF-2. In comparison to neonatal-derived iECs, patient 3 secreted significantly more VEGF in normoxic conditions (neonatal vs. patient 3, 0.3 pg/ml ± 0.1 vs. 4.77 pg/ml ± 1.1), and patients 2, 3, and 4 secreted significantly more VEGF in hypoxic conditions (neonatal vs. patient 2 vs patient 3 vs patient 4, 0.4 pg/ml ± 0.1 vs. 8.5 pg/ml ± 2.3 vs. 34.1 pg/ml ± 3.6 vs. 17.6 pg/ml ± 0.8). In comparison to neonatal-derived iECs, patient 2 and patient 4 secreted significantly more HGF in normoxic conditions (neonatal vs. patient 2 vs. patient 4, 6.6 pg/ml ± 0.1 vs. 11.2 pg/ml ± 6.4 vs. 16.9 pg/ml ± 1.2), and patient 4 secreted significantly more HGF in hypoxic conditions (neonatal vs. patient 4, 6.6 pg/ml ± 0.1 vs. 14.8 pg/ml ± 0.4). Secretion of FGF-1, SDF-1, and leptin was negligible for all cell lines.
Transplantation of neonatal-derived and patient-derived iECs enhances perfusion recovery in ischaemic hindlimbs

Recovery in perfusion to ischaemic hindlimbs was superior in mice treated with neonatal-derived iECs in comparison to those administered the vehicle control, EBM. The perfusion ratio was significantly enhanced in neonatal-derived iEC treatment group at days 8 (EBM vs. Neonatal-derived iECs; $0.47 \pm 0.03$ vs. $0.59 \pm 0.03$, $p < 0.05$), 10 (EBM vs. Neonatal-derived iECs; $0.55 \pm 0.03$ vs. $0.68 \pm 0.04$, $p < 0.05$), and 14 (EBM vs. Neonatal-derived iECs; $0.58 \pm 0.04$ vs. $0.77 \pm 0.06$, $p < 0.001$) (Fig 5) (Representative Doppler images in S2 Fig).

The recovery in perfusion to ischaemic hindlimbs observed in mice treated with patient-derived iECs was heterogeneous, differing across patients. Recovery in perfusion was significantly increased in mice treated with patient-derived iECs generated from patient 1 and patient 2, but was not increased in those treated with iECs generated from patient 3 (Fig 5).

Specifically, for patient-specific treatment we found the following:

**Patient 1:** The perfusion ratio was significantly enhanced in the patient 1 iEC treatment group at days 8 (Controls vs. Patient 1 iECs; $0.47 \pm 0.03$ vs. $0.66 \pm 0.04$, $p < 0.001$), 10 (Controls vs. Patient 1 iECs; $0.55 \pm 0.03$ vs. $0.72 \pm 0.06$, $p < 0.01$), and 14 (Controls vs. Patient 1 iECs; $0.58 \pm 0.04$ vs. $0.75 \pm 0.08$, $p < 0.01$).

**Patient 2:** The perfusion ratio was significantly enhanced in the Patient 2 iEC treatment group at days 4 (Controls vs. Patient 2 iECs; $0.28 \pm 0.02$ vs. $0.43 \pm 0.06$, $p < 0.01$), 6 (Controls vs. Patient 2 iECs; $0.41 \pm 0.04$ vs. $0.55 \pm 0.08$, $p < 0.05$), 8 (Controls vs. Patient 2 iECs; $0.47 \pm 0.03$ vs. $0.70 \pm 0.06$, $p < 0.001$), 10 (Controls vs. Patient 2 iECs; $0.55 \pm 0.04$ vs. $0.72 \pm 0.04$, $p < 0.01$), and 14 (Controls vs. Patient 2 iECs; $0.58 \pm 0.04$ vs. $0.77 \pm 0.04$, $p < 0.001$).
Patient 3: The perfusion ratio was not significantly enhanced for any time point for the patient 3 iEC treatment group.

3.5. Enhanced perfusion associated with increased capillary density in iEC-treated mice

In comparison to the control group, mice treated with neonatal-derived iECs demonstrated a positive trend to increased capillary density, though this was non-significant (control vs. neonatal-derived iECs; 1.31 ± 0.20 vs. 1.45 ± 0.32, p > 0.05), and mice treated with patient-derived iECs from patients 1 and 2 demonstrated significantly increased capillary density (control vs. patient 1 vs. patient 2; 1.31 ± 0.20 vs. 1.64 ± 0.25, p < 0.05 vs. 1.60 ± 0.15, p < 0.05) (Fig 5). The patient 3 treatment group had capillary density similar to that of controls (control vs. patient 3; 1.31 ± 0.20 vs. 1.31 ± 0.19, p > 0.99).

4. Discussion

The potential benefit of cellular therapies produced via reprogramming is particularly high in conditions characterised by a loss of cell quantity and functionality. With cellular dysfunction...
Fig 5. Blood perfusion recovery and capillary density in mice post hindlimb ischaemia surgery and treatment with iECs. (a) Blood perfusion recovery in ischaemic hindlimbs of mice treated with neonatal-derived iECs (red), patient-derived iECs from Patient 1 (green), Patient 2 (blue), and Patient 3 (grey), compared to controls (EBM) (black). Data were analysed by two-way repeated measures ANOVA and are presented as mean ± SEM (n = 23 for control group, n = 9 for iEC groups, * p < 0.05, ** p < 0.01, *** p < 0.001 compared to control. Asterix colour denotes associated treatment group). (b) Capillary density (capillaries/myocytes) for gastrocnemius muscle tissue from ischaemic hindlimbs collected at 14 days post-surgery for groups treated with neonatal-derived iECs (red), and patient-derived iECs for Patient 1 (green), Patient 2 (blue), and Patient 3 (grey), and control (EBM) (black). Data were analysed by one-way ANOVA with Bonferroni post hoc comparisons and are presented as mean ± SEM (n = 5–10 per group, * p < 0.05 compared to control).

https://doi.org/10.1371/journal.pone.0255075.g005
being a major contributor to the pathophysiology of severe PAD, the capacity to produce exogenous populations of cells via reprogramming techniques holds particular promise [12, 42–46]. Induced endothelial cells (iECs), a novel cell type produced via direct transdifferentiation of dermal fibroblasts to endothelial-like cells, represent a pro-angiogenic cell type that may be an effective cellular therapy in PAD [16, 22].

Use of viral vectors that integrate into somatic cell DNA limits the clinical viability of such cells due to safety concerns [16, 22]. Non-integrating vectors, such as mRNA, do not alter the host genome and are more acceptable for the production of clinical grade cells [47]. Furthermore, while allogenic iECs may have future clinical applications, autologous patient-derived iECs, produced directly from a patient’s own dermal fibroblasts, represent a theoretically ideal cell type with respect to safety and potentially efficacy. In this proof of concept study, we aimed to determine whether PAD patient-derived fibroblasts could be transdifferentiated to iECs using non-integrating mRNA and whether neonatal-derived and patient-derived iECs demonstrated comparable pro-angiogenic properties in vitro and in vivo.

We utilised an existing transdifferentiation protocol established for neonatal fibroblasts employing mRNA encoding endothelial transcription factors ETV2, FLI1, GATA2, and KLF4. Using this protocol we demonstrated that patient-derived fibroblasts could be successfully transdifferentiated into iECs. Our findings demonstrate that age and other cardiovascular risk factors are not barriers to iEC generation.

We compared neonatal and patient-derived iEC behaviour in vitro. In comparison to neonatal-derived iECs, the capacity for tubulogenesis was heterogeneous between patient-derived iEC lines. Previous studies have found variation in iEC phenotype, with iECs exhibiting effective tubulogenesis in one study [22], but not in the other [16]. Both neonatal and patient-derived iECs bound UEA 1 lectin, a marker of endothelial cells, and demonstrated limited uptake of acetylated-LDL. While both neonatal and patient-derived iECs demonstrated positive trends in their migration towards VEGF, these were not statistically significant. These results were in line with previous results using iECs produced using lentiviral vectors [16].

Since it is hypothesised that iECs are proangiogenic due to paracrine secretion of pro-angiogenic cytokines [16], we assessed the levels of several such cytokines secreted by neonatal and patient-derived iECs in vitro in normoxic and hypoxic conditions. Cytokine levels were heterogeneous between patient-derived iEC lines and between normoxic and hypoxic conditions, suggesting functional differences between the cell lines. Interestingly, we found that the observed secretion levels for VEGF appeared to be higher for patient-derived iECs than neonatal-derived iECs in both normoxic and hypoxic conditions, with patients 2, 3, and 4 secreting significantly more VEGF than neonatal iECs. It is noted that PAD patients have increased circulating VEGF [48–52], consistent with these results.

The small number of patients included in the study precluded us from determining significant associations between patient specific characteristics and the heterogeneity we observed in the in vitro studies. Further studies are required to determine associations between age, glycaemic control, PAD severity, and smoking history and in vitro behaviour of patient-derived iECs.

We found that intramuscular injection of neonatal-derived iECs produced using mRNA promote neo-angiogenesis in this model. This finding is consistent with existing results for iECs produced using lentiviral vectors [16]. Furthermore, in the first in vivo analysis of patient-derived iECs we found that patient-derived iECs have the capacity to promote neo-angiogenesis. Again, we noted heterogeneity in cell functionality across cell lines, with iECs derived from patients 1 and 2 showing significant improvement in perfusion, whilst iECs derived from patient 3 were not associated with any improvement. The observed improvements in perfusion post ischaemia were associated with increased capillary density in
gastrocnemius muscles. Of note, the heterogeneity between recovery in perfusion for patient-derived iECs was conserved in the data relating to capillary density; iECs from patients 1 and 2 demonstrated increased capillary density while patient 3 was not associated with an improvement.

The above in vivo results were surprising, especially given the lack of response to iECs derived from patient 3, due to the high VEGF secretion in vitro associated with this cell line. We hypothesised that there must be some degree of uncoupling between the in vitro and in vivo behaviour of the iECs, and that the degree of VEGF expression observed in the assay was not an indicator of in vivo function. In fact, given that patient 3 had a particularly high level of VEGF expression, but demonstrated no significant increase in perfusion, and given that PAD patients have higher circulating VEGF levels, we hypothesised that perhaps very high levels of secreted VEGF may in fact be an indicator for cellular dysfunction. In addition, we also noted that the patient 3 iEC line demonstrated reduced capacity to form tubules in comparison to other patient-derived iEC lines. This in vitro behaviour may indicate a level of cellular dysfunction that is reflected in the poor response in vivo. Further work is required to analyse the robustness of the pro-angiogenic effect of patient-derived iECs. Larger studies are also required to determine whether there are statistically significant biomarkers that can be used to predict in vivo function of patient-derived iECs.

The heterogeneity between patient-derived cell lines in our in vitro and in vivo studies suggests that there may be patient specific differences between iECs that contribute to altered iEC phenotype. The observed heterogeneity between cell lines is of clinical significance, as this might result in some patients having minimal benefit from any future iEC derived therapy, whilst others have significant benefit. This would result in wasted resources with respect to using poorly performing iECs in specific patients, and furthermore, might limit the ability to detect a positive response for particular individuals in any future clinical trial.

The observed heterogeneity in the in vitro and in vivo results for different patient-derived iEC lines may be explained by differences in patient age and disease severity. As displayed in Table 1, patients’ ages ranged from 64 to 88. Advanced age and a greater degree of exposure to cardiovascular risk factors such as hyperlipidaemia, hyperglycaemia, and hypertension may be associated with a higher degree of cellular dysfunction and impaired pro-angiogenic capacity in vivo in iECs. Indeed, we noted that glycaemic control, as indicated by the HbA1c values prior to surgery, was worse for patient 3 in comparison to patients 1 and 2, and may represent a possible causal factor in the reduced perfusion response exhibited for the associated cell line. A more comprehensive study utilizing a larger patient cohort is required to investigate further the impact of individual risk factors on iEC behaviour. The possibility exists that there are clinical markers, differences in cellular function, or detectable genetic or epigenetic differences, that could predict which patient-derived iECs lines will be significantly pro-angiogenic.

4.1. Study limitations

We note that the in vitro comparison of iEC phenotype performed for this study, whilst investigating tubulogenesis, lacked a definitive in vitro assessment of angiogenesis such as via aortic ring or three-dimensional spheroid assays [53]. Important mechanistic differences differentiating effective and ineffective angiogenesis resulting from iECs could be elucidated by such assays, and would be a useful extension of this work. In addition, patient donors recruited for this study differed in gender, age, disease severity, as well as past medical history and current pharmacotherapy. The effects that patient specific factors have on iEC function have important implications for the clinical utility of this cell type. iECs derived from particular patient subgroups may be particularly effective or ineffective and this information is particularly
important in developing iECs and other similar cell types for therapeutic uses in the future. Our study was not large enough to detect such differences, and a more extensive investigation of patient-derived iECs is warranted.

5. Conclusions

Neonatal fibroblasts and dermal fibroblasts derived from PAD patients can both be transdifferentiated to endothelial-like iECs using mmRNA. Though heterogeneity between patient-derived iECs was identified, both neonatal-derived and patient-derived iECs demonstrated qualitatively similar in vitro behaviour. Both neonatal-derived and patient-derived iECs demonstrated the capacity for pro-angiogenic behaviour in vivo in a hindlimb ischaemia mouse model of PAD, though the pro-angiogenic response was not consistent for all patient-derived iECs. These findings suggest that developing patient-derived iECs for therapeutic use may be feasible.

Supporting information

S1 Fig. iEC Transwell migration towards VEGF. Transwell migration towards VEGF relative to migration towards inert control. 100% represents level of migration observed towards inert control for each individual cell line. Data were analysed by two-way ANOVA and are presented as mean ± SEM.

S2 Fig. Representative laser Doppler images for improvements in hindlimb perfusion. (a) control (EBM), (b) neonatal-derived iEC group across days 1, 2, 4, 6, 8, 10, 14, post-surgery.

S3 Fig. Representative fluorescence microscopy images showing gastrocnemius muscle tissue from ischaemic hindlimbs collected at 14 days post-surgery, CD31 (red), Laminin (blue), smooth muscle actin (green); (a) control; (b) neonatal-derived iEC group; (c)-(e) patient-derived iECs: (c) patient 1; (d) patient 2; (e) patient 3. All scale bars are 200 μm.

Author Contributions

Conceptualization: Sanjay Patel.
Funding acquisition: Sanjay Patel.
Investigation: Jack D. Hywood, Sara Sadeghipour, Zoe E. Clayton, Jun Yuan.
Methodology: Jack W. T. Wong, John P. Cooke, Sanjay Patel.
Resources: Colleen Stubbs, Jack W. T. Wong, John P. Cooke.
Writing – original draft: Jack D. Hywood.

References

1. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. The Lancet. 2013 Oct 19; 382(9901):1329–40.
2. Peach G, Griffin M, Jones KG, Thompson MM, Hinchcliffe RJ. Diagnosis and management of peripheral arterial disease. BMJ. 2012 Aug 14; 345:e5208. https://doi.org/10.1136/bmj.e5208 PMID: 22893640

3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS medicine. 2006 Nov 28; 3(11):e442. https://doi.org/10.1371/journal.pmed.0030442 PMID: 17132052

4. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014 Jan 21; 129(3):399–410. https://doi.org/10.1161/01.cir.0000442015.53336.12 PMID: 24446411

5. Layden J, Michaels J, Birmingham S, Higgins B. Diagnosis and management of lower limb arterial disease: summary of NICE guidance. BMJ. 2012 Aug 8; 345:e4947. https://doi.org/10.1136/bmj.e4947 PMID: 22875949

6. Varu VN, Hogg ME, Kibbe MR. Critical limb ischemia. Journal of vascular surgery. 2010 Jan 1; 51(1):230–41. https://doi.org/10.1016/j.jvs.2009.08.073 PMID: 20117502

7. Baumann F, Willenberg T, Do DD, Keo HH, Baumgartner I, Diehm N. Endovascular revascularization of below-the-knee arteries: prospective short-term angiographic and clinical follow-up. Journal of vascular and interventional radiology. 2011 Dec 1; 22(12):1665–73. https://doi.org/10.1016/j.jvir.2011.08.028 PMID: 22019178

8. Schmidt A, Ulrich M, Winkler B, Klaffling C, Bausback Y, Bräunlich S, et al. Angiographic patency and clinical outcome after balloon-angioplasty for extensive infrapopliteal arterial disease. Catheterization and Cardiovascular Interventions. 2010 Dec 1; 76(7):1047–54. https://doi.org/10.1002/ccd.22658 PMID: 20518006

9. Baumann F, Fust J, Peter Engelberger, Hügel U, Baumgartner I, Diehm N. Early recall after balloon angioplasty of tibial artery obstructions in patients with critical limb ischemia. Journal of endovascular therapy. 2014 Feb; 21(1):44–51. https://doi.org/10.1583/13-4486MR.1 PMID: 24502483

10. Thomas AC. Targeted treatments for restenosis and vein graft disease. ISRN Vascular Medicine. 2012 Dec 9:2012.

11. Faber JE, Chilian WM, Deindl E, van Royen N, Simons M. A brief etymology of the collateral circulation. Arteriosclerosis, thrombosis, and vascular biology. 2014 Sep; 34(9):1854–9. https://doi.org/10.1161/ATVBAHA.114.303929 PMID: 25012127

12. Cooke JP, Losordo DW. Modulating the vascular response to limb ischemia: angiogenic and cell therapies. Circulation research. 2015 Apr 24; 116(9):e72–9. https://doi.org/10.1161/CIRCRESAHA.115.303565 PMID: 25080728

13. Lee AS, Xu D, Plews JR, Nguyen PK, Nag D, Lyons JK, et al. Preclinical derivation and imaging of autologous transplanted canine induced pluripotent stem cells. Journal of Biological Chemistry. 2011 Sep 30; 286(37):32697–704. https://doi.org/10.1074/jbc.M111.235739 PMID: 21719696

14. Rufaihah AJ, Huang NF, Jamé S, Lee JC, Nguyen HN, Byers B, et al. Endothelial cells derived from human iPSCs increase capillary density and improve perfusion in a mouse model of peripheral arterial disease. Arteriosclerosis, thrombosis, and vascular biology. 2011 Nov; 31(11):e72–9. https://doi.org/10.1161/ATVBAHA.111.230938 PMID: 21836062

15. Lai WH, Ho JC, Chan YC, Ng JH, Au KW, Wong LY, et al. Attenuation of hind-limb ischemia in mice with endothelial-like cells derived from different sources of human stem cells. PloS one. 2013 Mar 5; 8(3):e57876. https://doi.org/10.1371/journal.pone.0057876 PMID: 23472116

16. Clayton ZE, Yuen GS, Sadeghpour S, Hywood JD, Wong JW, Huang NF, et al. A comparison of the pro-angiogenic potential of human induced pluripotent stem cell derived endothelial cells and induced endothelial cells in a murine model of peripheral arterial disease. International journal of cardiology. 2017 May 1; 234:81–9. https://doi.org/10.1016/j.ijcard.2017.01.125 PMID: 28209385

17. Clayton ZE, Tan RP, Miravet MM, Lennartsson K, Cooke JP, Bursill CA, et al. Induced pluripotent stem cell-derived endothelial cells promote angiogenesis and accelerate wound closure in a murine excisional wound healing model. Bioscience reports. 2018 Aug 31; 38(4):BSR20180563. https://doi.org/10.1042/BSR20180563 PMID: 29976773

18. Tan RP, Chan AH, Lennartsson K, Miravet MM, Lee BS, Pnjak-Kovacina J, et al. Integration of induced pluripotent stem cell-derived endothelial cells with poly-caprolactone/gelatin-based electrospun scaffolds for enhanced therapeutic angiogenesis. Stem cell research & therapy. 2018 Dec; 9(1):70. https://doi.org/10.1186/s13287-018-0824-2 PMID: 29626916

19. Lai WH, Ho JC, Chan YC, Ng JH, Au KW, Wong LY, et al. Induced pluripotent stem cell-derived endothelial cells promote angiogenesis and accelerate wound closure in a murine excisional wound healing model. Bjorn Eng. 2012 Aug 14; 345:e5208. https://doi.org/10.1136/bmj.e5208 PMID: 22893640

20. Li J, Huang NF, Zou J, Laurent TJ, Lee JC, Okogbaa J, et al. Conversion of human fibroblasts to functional endothelial cells by defined factors. Arteriosclerosis, thrombosis, and vascular biology. 2013 Jun; 33(6):1566–75. https://doi.org/10.1161/ATVBAHA.112.301167 PMID: 23520160

21. Han JK, Chang SH, Cho HJ, Choi SB, Ahn HS, Lee J, et al. Direct conversion of adult skin fibroblasts to endothelial cells by defined factors. Circulation. 2014 Sep 30; 130(14):1168–78. https://doi.org/10.1161/CIRCULATIONAHA.113.007727 PMID: 25186941
21. Sayed N, Wong WT, Ospino F, Meng S, Lee J, Jha A, et al. Transdifferentiation of human fibroblasts to endothelial cells: role of innate immunity. Circulation. 2015 Jan 20; 131(3):300–9. https://doi.org/10.1161/CIRCULATIONAHA.103.073942 PMID: 25359165

22. Wong WT, Cooke JP. Therapeutic transdifferentiation of human fibroblasts into endothelial cells using forced expression of lineage-specific transcription factors. Journal of tissue engineering. 2016 Feb 1; 7:2041731416628329. https://doi.org/10.1177/2041731416628329 PMID: 27081470

23. Cooke JP. Therapeutic transdifferentiation: a novel approach for vascular disease. Circulation research. 2013 Mar 1; 112(5):748–50. https://doi.org/10.1161/CIRCRESAHA.113.301053 PMID: 23449543

24. Kelaini S, Cochrane A, Margariti A. Direct reprogramming of adult cells: avoiding the pluripotent state. Stem cells and cloning: advances and applications. 2014; 7:19. https://doi.org/10.2147/SCCAA.S38006 PMID: 24627642

25. Xu J, Du Y, Deng H. Direct lineage reprogramming: strategies, mechanisms, and applications. Cell stem cell. 2015 Feb 5; 16(2):119–34. https://doi.org/10.1016/j.stem.2015.01.013 PMID: 25658369

26. Zhao T, ZhangZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011 Jun; 474(7350):212. https://doi.org/10.1038/nature10135 PMID: 21572395

27. Kang X, Yu Q, Huang Y, Song B, Chen Y, Gao X, et al. Effects of integrating and non-integrating reprogramming methods on copy number variation and genomic stability of human induced pluripotent stem cells. PLoS One 2015; 10(7):e0131128. https://doi.org/10.1371/journal.pone.0131128 PMID: 26131765

28. Laurent LC, Ullitsky I, Slavin I, Tran H, Schork A, Morey R, et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human escs and ipscs during reprogramming and time in culture. Cell stem cell 2011; 8(1):106–18. https://doi.org/10.1016/j.stem.2010.02.012 PMID: 21211785

29. Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011; 471(7336):68–73. https://doi.org/10.1038/nature09798 PMID: 21289626

30. Martins-Taylor K, Nisler BS, Taapken SM, Compton T, Crandall L, Montgomery KD, et al. Recurrent copy number variations in human induced pluripotent stem cells. Nature biotechnology 2011; 29 (6):488–91. https://doi.org/10.1038/nbt.1890 PMID: 21654665

31. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell stem cell. 2010 Nov 5; 7(5):618–30. https://doi.org/10.1016/j.stem.2010.08.012 PMID: 20888316

32. Mandal PK, Rossi DJ. Reprogramming human fibroblasts to pluripotency using modified mRNA. Nature protocols. 2013 Mar; 8(3):568. https://doi.org/10.1038/nprot.2013.019 PMID: 23429718

33. Yakubov E, Rechavi G, Rozenblatt S, Givol D. Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. Biochemical and biophysical research communications. 2010 Mar 26; 394(1):189–93. https://doi.org/10.1016/j.bbrc.2010.02.150 PMID: 20188704

34. Simeonov KP, Uppal H. Direct reprogramming of human fibroblasts to hepatocyte-like cells by synthetic modified mRNAs. PloS one. 2014 Jun 25; 9(6):e100134. https://doi.org/10.1371/journal.pone.0100134 PMID: 24963715

35. Kim J, Kim KP, Lim KT, Lee SC, Yoon J, Song G, et al. Generation of integration-free induced hepatocyte-like cells from mouse fibroblasts. Scientific reports. 2015 Oct 27; 5:15706. https://doi.org/10.1038/srep15706 PMID: 26503743

36. Kogut I, McCarthy SM, Pavlova M, Astling DP, Chen X, Jakimenko A, et al. High-efficiency RNA-based reprogramming of human primary fibroblasts. Nature communications. 2018 Feb 21; 9(1):745. https://doi.org/10.1038/s41467-018-03190-3 PMID: 29467427

37. Grath A, Dai G. Direct cell reprogramming for tissue engineering and regenerative medicine. Journal of biological engineering 2019; 13(1):14.

38. Qin H, Zhao A, Fu X. Small molecules for reprogramming and transdifferentiation. Cellular and molecular life sciences 2017; 74(19):3553–75. https://doi.org/10.1007/s00018-017-2586-x PMID: 28698932

39. Vangipuram M, Ting D, Kim S, Diaz R, Schüle B. Skin punch biopsy explant culture for derivation of primary human fibroblasts. JoVE (Journal of Visualized Experiments). 2013 Jul 1; 7(77):e3779. https://doi.org/10.3791/7779 PMID: 23852182

40. Kariko K, Muramatsu H, Ludwig J. Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic acids research. 2011 Sep 2; 39(21):e142–. https://doi.org/10.1093/nar/gkr695 PMID: 21890902

41. Niiyama H, Huang NF, Rollins MD, Cooke JP. Murine model of hindlimb ischemia. JoVE (Journal of Visualized Experiments). 2009 Jan 21(23):e1035.
42. Morishita T, Uzui H, Nakano A, Mitsuke Y, Geshi T, Ueda T, et al. Number of endothelial progenitor cells in peripheral artery disease as a marker of severity and association with pentraxin-3, malondialdehyde-modified low-density lipoprotein and membrane type-1 matrix metalloproteinase. Journal of atherosclerosis and thrombosis. 2012; 19(2):149–58. https://doi.org/10.5551/jat.10074 PMID: 22123215

43. Teraa M, Sprengers RW, Westerweel PE, Gremmels H, Goumans MJ, Teerlink T, et al. Bone marrow alterations and lower endothelial progenitor cell numbers in critical limb ischemia patients. PLoS one. 2013 Jan 31; 8(1):e55592. https://doi.org/10.1371/journal.pone.0055592 PMID: 23383236

44. Rivard A, Fabre JE, Silver M, Chen D, Murohara T, Kearney M, et al. Age-dependent impairment of angiogenesis. Circulation. 1999 Jan 12; 99(1):111–20. https://doi.org/10.1161/01.cir.99.1.111 PMID: 9884387

45. Wang J, Peng X, Lassance-Soares RM, Najafi AH, Alderman LO, Sood S, et al. Aging-induced collateral dysfunction: impaired responsiveness of collaterals and susceptibility to apoptosis via dysfunctional eNOS signaling. Journal of cardiovascular translational research. 2011 Dec 1; 4(6):779–89. https://doi.org/10.1007/s12265-011-9280-4 PMID: 21538183

46. Jung C, Rafnsson A, Shemyakin A, Böhm F, Pernow J. Different subpopulations of endothelial progenitor cells and circulating apoptotic progenitor cells in patients with vascular disease and diabetes. International journal of cardiology. 2010 Sep 3; 143(3):368–72. https://doi.org/10.1016/j.ijcard.2009.03.075 PMID: 19398138

47. Clayton ZE, Sadeghipour S, Patel S. Generating induced pluripotent stem cell derived endothelial cells and induced endothelial cells for cardiovascular disease modelling and therapeutic angiogenesis. International journal of cardiology. 2015 Oct 15; 197:116–22. https://doi.org/10.1016/j.ijcard.2015.06.038 PMID: 26123569

48. Makin AJ, Chung NA, Silverman SH, Gregory YH. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis? Clinical Science. 2003 Apr 1; 104(4):397–404. https://doi.org/10.1042/CS20020182 PMID: 12653684

49. Botti C, Mainone C, Dogliotti G, Russo P, Signoriello G, Molinari AM, et al. Circulating cytokines present in the serum of peripheral arterial disease patients induce endothelial dysfunction. Journal of biological regulators and homeostatic agents. 2012 Jan 1; 26(1):67. PMID: 22475098

50. Findley CM, Mitchell RG, Duscha BD, Annex BH, Kontos CD. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. Journal of the American College of Cardiology. 2008 Jul 29; 52(5):387–93. https://doi.org/10.1016/j.jacc.2008.02.045 PMID: 18652948

51. Brandao D, Costa C, Canedo A, Vaz G, Pignatelli D. Endogenous vascular endothelial growth factor and angioptelin-2 expression in critical limb ischemia. International angiology: a journal of the International Union of Angiology. 2011 Feb; 30(1):25–34. PMID: 21248670

52. Bleda S, de Haro J, Acin F, Varela C, Esparza L. Enhanced vascular endothelial growth factor gene expression in ischaemic skin of critical limb ischaemia patients. International journal of vascular medicine. 2012;2012. https://doi.org/10.1155/2012/691528 PMID: 22536509

53. Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, et al. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis. 2018 Aug; 21(3):425–532. https://doi.org/10.1007/s10456-018-9613-x PMID: 29766399